Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other protocol defined criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
226 participants in 7 patient groups
Loading...
Central trial contact
BeiGene
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal